BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34105142)

  • 1. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
    J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies for hypereosinophilic syndromes.
    Antoniu SA
    Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
    J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
    Iurlo A; Cattaneo D; Gianelli U
    Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of hypereosinophilic syndromes--the first 100 years.
    Butterfield JH; Weiler CR
    Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
    Kuang FL; Klion AD
    J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypereosinophilic syndrome: an update.
    Wilkins HJ; Crane MM; Copeland K; Williams WV
    Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
    Helbig G; Kyrcz-Krzemień S
    Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat hypereosinophilic syndromes.
    Klion AD
    Blood; 2015 Aug; 126(9):1069-77. PubMed ID: 25964669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Hypereosinophilic Syndromes in Childhood].
    Leu T; Simon HU; Hebestreit H; Kunzmann S
    Klin Padiatr; 2015 Nov; 227(6-7):308-13. PubMed ID: 26267413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypereosinophilic syndromes].
    Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
    Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Hypereosinophilic Syndromes.
    Roufosse F
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
    Reiter A; Lefevre G; Cid MC; Kwon N; Mavropolou E; Yancey SW; Steinfeld J
    Front Immunol; 2022; 13():840974. PubMed ID: 35493455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series.
    Carruthers MN; Park S; Slack GW; Dalal BI; Skinnider BF; Schaeffer DF; Dutz JP; Law JK; Donnellan F; Marquez V; Seidman M; Wong PC; Mattman A; Chen LY
    Eur J Haematol; 2017 Apr; 98(4):378-387. PubMed ID: 28005278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
    Hellmich B; Holl-Ulrich K; Gross WL
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.